| Nov 15 |
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
|
| Nov 12 |
iTeos Therapeutics GAAP EPS of -$1.05 beats by $0.12
|
| Nov 12 |
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Oct 24 |
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
|
| Sep 16 |
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
|
| Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
|
| Sep 15 |
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
|
| Sep 14 |
TIGIT drug from iTeos shrinks lung tumors in trial
|
